MX366832B - Composiciones de farmaco de liberacion sostenida convenientemente implantables. - Google Patents
Composiciones de farmaco de liberacion sostenida convenientemente implantables.Info
- Publication number
- MX366832B MX366832B MX2016016614A MX2016016614A MX366832B MX 366832 B MX366832 B MX 366832B MX 2016016614 A MX2016016614 A MX 2016016614A MX 2016016614 A MX2016016614 A MX 2016016614A MX 366832 B MX366832 B MX 366832B
- Authority
- MX
- Mexico
- Prior art keywords
- sustained release
- release drug
- drug compositions
- implantable sustained
- conveniently
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Oral & Maxillofacial Surgery (AREA)
Abstract
La invención provee formulaciones farmacéuticas líquidas aplicables con jeringa, sólidas implantables y en gel inyectables, biocompatibles y biodegradables, útiles para el tratamiento de estados de enfermedad sistémicos y locales.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61448404P | 2004-10-01 | 2004-10-01 | |
US70966505P | 2005-08-19 | 2005-08-19 | |
PCT/US2005/034822 WO2006039336A2 (en) | 2004-10-01 | 2005-09-27 | Conveniently implantable sustained release drug compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
MX366832B true MX366832B (es) | 2019-07-24 |
Family
ID=36143017
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007003968A MX2007003968A (es) | 2004-10-01 | 2005-09-27 | Composiciones de farmaco de liberacion sostenida convenientemente implantables. |
MX2011005101A MX344532B (es) | 2004-10-01 | 2005-09-27 | Composiciones de farmaco de liberacion sostenida convenientemente implantables. |
MX2016016614A MX366832B (es) | 2004-10-01 | 2005-09-27 | Composiciones de farmaco de liberacion sostenida convenientemente implantables. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007003968A MX2007003968A (es) | 2004-10-01 | 2005-09-27 | Composiciones de farmaco de liberacion sostenida convenientemente implantables. |
MX2011005101A MX344532B (es) | 2004-10-01 | 2005-09-27 | Composiciones de farmaco de liberacion sostenida convenientemente implantables. |
Country Status (13)
Country | Link |
---|---|
US (1) | US7906136B2 (es) |
EP (3) | EP2452670A1 (es) |
JP (6) | JP5682991B2 (es) |
KR (2) | KR101506925B1 (es) |
CN (2) | CN101890167B (es) |
AU (2) | AU2005292145C1 (es) |
BR (1) | BRPI0516830A (es) |
CA (1) | CA2582096C (es) |
HK (1) | HK1107672A1 (es) |
MX (3) | MX2007003968A (es) |
MY (1) | MY167123A (es) |
NZ (1) | NZ554426A (es) |
WO (1) | WO2006039336A2 (es) |
Families Citing this family (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2850282B1 (fr) | 2003-01-27 | 2007-04-06 | Jerome Asius | Implant injectable a base de ceramique pour le comblement de rides, depressions cutanees et cicatrices, et sa preparation |
EP1682132A1 (en) * | 2003-09-18 | 2006-07-26 | Macusight, Inc. | Transscleral delivery |
US8591885B2 (en) * | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
PT1781264E (pt) | 2004-08-04 | 2013-10-16 | Evonik Corp | Métodos para o fabrico de dispositivis de administração e dispositivos para a mesma |
US9993558B2 (en) | 2004-10-01 | 2018-06-12 | Ramscor, Inc. | Sustained release eye drop formulations |
US7999072B2 (en) | 2004-11-22 | 2011-08-16 | Centre National De La Recherche Scientifique (Cnrs) | Mutated netrin-4, fragments thereof and their use as medicines |
EP1848431B1 (en) | 2005-02-09 | 2016-02-03 | Santen Pharmaceutical Co., Ltd. | Liquid formulations for treatment of diseases or conditions |
US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
US7592330B2 (en) * | 2005-08-08 | 2009-09-22 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
US20070212397A1 (en) * | 2005-09-15 | 2007-09-13 | Roth Daniel B | Pharmaceutical delivery device and method for providing ocular treatment |
AU2006330526B2 (en) * | 2005-12-22 | 2012-09-27 | Oakwood Laboratories, Llc | Sublimable sustained release delivery system and method of making same |
US7756524B1 (en) | 2006-01-31 | 2010-07-13 | Nextel Communications Inc. | System and method for partially count-based allocation of vocoder resources |
WO2009113972A2 (en) * | 2006-02-08 | 2009-09-17 | Tyrx Pharma, Inc. | Temporarily stiffened mesh prostheses |
US8591531B2 (en) | 2006-02-08 | 2013-11-26 | Tyrx, Inc. | Mesh pouches for implantable medical devices |
WO2007092620A2 (en) | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
WO2007100609A2 (en) * | 2006-02-24 | 2007-09-07 | Albert Einstein College Of Medicine Of Yeshiva University | Electron transfer through glassy matrices |
ES2563288T3 (es) | 2006-03-23 | 2016-03-14 | Santen Pharmaceutical Co., Ltd | Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular |
US20070265329A1 (en) * | 2006-05-12 | 2007-11-15 | Devang Shah T | Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) |
US20070280902A1 (en) * | 2006-06-01 | 2007-12-06 | Laura Rabinovich-Guilatt | Method for treating eye disease or conditions affecting the posterior segment of the eye |
ES2422864T3 (es) | 2006-08-09 | 2013-09-16 | Intarcia Therapeutics, Inc | Sistemas de liberación osmótica y unidades de pistón |
US20100179175A1 (en) * | 2006-08-23 | 2010-07-15 | Sivak Jeremy M | Use of pkc inhibitors in ocular diseases |
WO2008033924A2 (en) * | 2006-09-12 | 2008-03-20 | Board Of Regents Of The University Of Nebraska | Methods and compositions for targeted delivery of therapeutic agents |
US20080138350A1 (en) * | 2006-10-20 | 2008-06-12 | Bennett Michael D | Process for use of fluoroquinolones to reduce or modulate inflammation due to eye disease or ophthalmic surgery |
ATE475686T1 (de) * | 2006-10-31 | 2010-08-15 | Surmodics Pharmaceuticals Inc | Kugelförmige polymer-teilchen |
US9023114B2 (en) | 2006-11-06 | 2015-05-05 | Tyrx, Inc. | Resorbable pouches for implantable medical devices |
ES2791698T3 (es) | 2006-12-18 | 2020-11-05 | Takeda Pharmaceuticals Co | Composición de liberación sostenida y método para producir la misma |
PT2131821T (pt) * | 2007-03-07 | 2018-10-10 | Abraxis Bioscience Llc | Nanopartícula que compreende rapamicina e albumina como agente anticancerígeno |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
US8927019B2 (en) * | 2007-06-01 | 2015-01-06 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
US20080317805A1 (en) * | 2007-06-19 | 2008-12-25 | Mckay William F | Locally administrated low doses of corticosteroids |
AU2008271911B2 (en) * | 2007-06-29 | 2014-08-07 | Phovitreal Pty Ltd | Treatment or prophylaxis or neurological or neuropsychiatric disorders via ocular administration |
KR100882817B1 (ko) * | 2007-07-20 | 2009-02-10 | 숙명여자대학교산학협력단 | 보툴리늄 독소를 유효성분으로 포함하는 지방세포 생착증진용 약학적 조성물 |
US8124601B2 (en) * | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US20110097408A1 (en) * | 2007-12-10 | 2011-04-28 | O'malley Bert W | Chitosan-based matrices and uses thereof |
CA2709712C (en) | 2007-12-20 | 2016-05-10 | Surmodics Pharmaceuticals, Inc. | Process for preparing microparticles having a low residual solvent volume |
US20110104253A1 (en) | 2008-01-18 | 2011-05-05 | Horst Kief | Agent for intra-articular injection |
US8343140B2 (en) | 2008-02-13 | 2013-01-01 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US20090226547A1 (en) * | 2008-03-05 | 2009-09-10 | Gilbard Jeffrey P | Dietary Supplement For Eye Health |
US9132119B2 (en) | 2008-04-18 | 2015-09-15 | Medtronic, Inc. | Clonidine formulation in a polyorthoester carrier |
US8883768B2 (en) * | 2008-04-18 | 2014-11-11 | Warsaw Orthopedic, Inc. | Fluocinolone implants to protect against undesirable bone and cartilage destruction |
US9125917B2 (en) * | 2008-04-18 | 2015-09-08 | Warsaw Orthopedic, Inc. | Fluocinolone formulations in a biodegradable polymer carrier |
WO2010009291A1 (en) * | 2008-07-16 | 2010-01-21 | Surmodics Pharmaceuticals, Inc. | Process for preparing microparticles containing bioactive peptides |
US8697155B2 (en) * | 2008-07-22 | 2014-04-15 | Mayo Foundation For Medical Education And Research | Treatment of obesity and related disorders |
US20110212127A1 (en) * | 2008-09-24 | 2011-09-01 | Stabilitech Ltd. | Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine |
AU2009295623A1 (en) * | 2008-09-24 | 2010-04-01 | Stabilitech Ltd | Method for preserving polypeptides using a sugar and polyethyleneimine |
US8729097B2 (en) * | 2008-10-06 | 2014-05-20 | The Johns Hopkins University | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders |
CN102238949A (zh) | 2008-10-09 | 2011-11-09 | 拉姆斯科股份有限公司 | 治疗干眼综合征的组合物和方法 |
CN104887389B (zh) | 2009-01-29 | 2017-06-23 | 弗赛特影像4股份有限公司 | 后段给药 |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
WO2011031476A2 (en) * | 2009-08-25 | 2011-03-17 | Emory University | Compositions and methods for treatment or prevention of post-operative organ or tissue inflammation |
EP3735944A1 (en) | 2009-09-28 | 2020-11-11 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
US20110097380A1 (en) * | 2009-10-28 | 2011-04-28 | Warsaw Orthopedic, Inc. | Clonidine formulations having antimicrobial properties |
ES2708989T3 (es) | 2010-03-31 | 2019-04-12 | Stabilitech Biopharma Ltd | Método de conservación de adyuvantes de alumbre y vacunas potenciadas con alumbre |
ES2543795T3 (es) | 2010-03-31 | 2015-08-21 | Stabilitech Ltd. | Estabilización de partículas virales |
US20130164296A1 (en) | 2010-03-31 | 2013-06-27 | Jeffrey Drew | Excipients for Stabilising Viral Particles, Polypeptides or Biological Material |
DE102010013898A1 (de) * | 2010-04-01 | 2011-10-06 | Acino Ag | Implantatskanüle mit Implantat und Verfahren zum Befestigen von Implantaten in einer Injektionskanüle |
DK2600930T3 (da) | 2010-08-05 | 2021-03-01 | Forsight Vision4 Inc | Injektionsapparat til lægemiddelafgivelse |
AU2011285548B2 (en) | 2010-08-05 | 2014-02-06 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
US9492315B2 (en) | 2010-08-05 | 2016-11-15 | Forsight Vision4, Inc. | Implantable therapeutic device |
CN101972236A (zh) * | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的缓释制剂 |
WO2012068549A2 (en) | 2010-11-19 | 2012-05-24 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
WO2012097258A2 (en) * | 2011-01-15 | 2012-07-19 | The Regents Of The University Of California | Formulations for the prevention and treatment of wolbachia-related disease |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
DK2717914T3 (da) * | 2011-06-10 | 2020-01-20 | Ramscor Inc | Depotformuleringer til administration af proteiner til øjet og fremgangsmåder til fremstilling deraf |
WO2013003620A2 (en) | 2011-06-28 | 2013-01-03 | Forsight Vision4, Inc. | Diagnostic methods and apparatus |
EP2739252A4 (en) | 2011-08-05 | 2015-08-12 | Forsight Vision4 Inc | SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE |
PL2755600T3 (pl) | 2011-09-16 | 2021-09-20 | Forsight Vision4, Inc. | Urządzenie do wymiany płynów |
GB201117233D0 (en) | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
US20130190839A1 (en) * | 2012-01-20 | 2013-07-25 | Jane Rapsey | Drug delivery using a sacrificial host |
WO2013116061A1 (en) | 2012-02-03 | 2013-08-08 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
CA2871778C (en) | 2012-05-03 | 2022-09-13 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
EP2844227B1 (en) | 2012-05-03 | 2020-11-18 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
US20140105956A1 (en) * | 2012-10-11 | 2014-04-17 | Rupak BANERJEE | Biodegradable polymer based microimplant for ocular drug delivery |
US9555054B2 (en) | 2012-11-21 | 2017-01-31 | University Of Louisville Research Foundation, Inc. | Compositions and methods for reducing oxidative damage |
ES2653765T3 (es) | 2012-12-21 | 2018-02-08 | Sanofi | Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón |
EP2950782B1 (en) | 2013-01-31 | 2017-12-27 | Icon Bioscience, Inc. | Sustained release formulations for the treatment of intraocular pressure or glaucoma |
CA2900652C (en) | 2013-02-15 | 2021-05-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
BR112015020139A2 (pt) | 2013-02-20 | 2017-07-18 | Kala Pharmaceuticals Inc | compostos terapêuticos e usos dos mesmos |
WO2014152959A1 (en) | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
CA2907681C (en) | 2013-03-28 | 2022-11-22 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
GB2516137B (en) * | 2013-04-09 | 2016-02-17 | Cresset Biomolecular Discovery Ltd | The local treatment of inflammatory ophthalmic diseases |
ES2902951T3 (es) | 2013-05-24 | 2022-03-30 | Icon Bioscience Inc | Uso de dexametasona de liberación sostenida en la inflamación después de cirugía de cataratas |
CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US9458169B2 (en) | 2013-11-01 | 2016-10-04 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
EA201692083A1 (ru) | 2014-04-16 | 2017-03-31 | Вейкс-Фарма Гмбх | Фармацевтическая композиция для ветеринарии и ее применение |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
AU2015289625B2 (en) | 2014-07-15 | 2019-10-10 | Forsight Vision4, Inc. | Ocular implant delivery device and method |
US9707184B2 (en) | 2014-07-17 | 2017-07-18 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
WO2016019165A1 (en) | 2014-07-30 | 2016-02-04 | Massachusetts Eye And Ear Infirmary | Methotrexate for proliferative vitreoretinopathy |
KR20170040798A (ko) | 2014-08-08 | 2017-04-13 | 포사이트 비젼4, 인크. | 수용체 티로신 키나제 억제제의 안정한 가용성 제제 및 그의 제조 방법 |
CA2958195A1 (en) * | 2014-08-15 | 2016-02-18 | PixarBio Corporation | Compositions for inhibiting inflammation in a subject with a spinal cord injury and methods of using the same |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
CA2964628A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
GB2535427A (en) | 2014-11-07 | 2016-08-24 | Nicoventures Holdings Ltd | Solution |
CN110478119B (zh) | 2014-11-10 | 2022-04-15 | 弗赛特影像4股份有限公司 | 可膨胀药物递送装置和使用方法 |
WO2016130478A1 (en) | 2015-02-09 | 2016-08-18 | University Of Louisville Research Foundation, Inc. | Ophthalmic compositions and methods for reducing oxidative damage to an eye lens |
JP2016175900A (ja) * | 2015-03-18 | 2016-10-06 | 参天製薬株式会社 | 徐放性医薬組成物 |
EP4278996A3 (en) | 2015-06-03 | 2024-01-24 | i2o Therapeutics, Inc. | Implant placement systems |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
CN105496947A (zh) * | 2015-11-19 | 2016-04-20 | 苏州桓晨医疗科技有限公司 | 一种药物缓释制剂 |
CN108430405B (zh) | 2015-11-20 | 2021-04-13 | 弗赛特影像4股份有限公司 | 用于缓释药物递送装置的多孔结构 |
EP3439591B1 (en) | 2016-04-05 | 2020-09-23 | ForSight Vision4, Inc. | Implantable ocular drug delivery devices |
AU2017268161B2 (en) | 2016-05-16 | 2020-03-12 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
WO2017218284A1 (en) * | 2016-06-13 | 2017-12-21 | Massachusetts Eye And Ear Infirmary | Local orbital therapy for thyroid eye disease |
US10682340B2 (en) | 2016-06-30 | 2020-06-16 | Durect Corporation | Depot formulations |
WO2018005777A1 (en) | 2016-06-30 | 2018-01-04 | Durect Corporation | Depot formulations |
US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CA3036065A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
WO2018048750A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
JP2019526611A (ja) | 2016-09-13 | 2019-09-19 | アラーガン、インコーポレイテッドAllergan,Incorporated | 非タンパク質クロストリジウム毒素組成物 |
CA3049034A1 (en) | 2017-01-03 | 2018-07-12 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug |
GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
CA3082891A1 (en) | 2017-11-21 | 2019-05-31 | Forsight Vision4, Inc. | Fluid exchange apparatus for expandable port delivery system and methods of use |
CN111655171B (zh) | 2018-02-08 | 2024-03-08 | 泰尔茂株式会社 | 医疗器具以及使用其的愈合促进器械 |
US11065003B2 (en) | 2018-03-19 | 2021-07-20 | Terumo Kabushiki Kaisha | Treatment method for joining biological organs |
CN112367981B (zh) | 2018-05-01 | 2024-06-04 | 奇比有限公司 | 用于将药剂无创地持续递送至眼部的液体储库 |
JP2021523222A (ja) * | 2018-05-01 | 2021-09-02 | チビ,インコーポレイティド | 網膜への薬剤の持続送達のための点眼剤および方法 |
EP3845148A4 (en) | 2018-09-27 | 2021-11-03 | TERUMO Kabushiki Kaisha | ADHESION PROMOTION DEVICE AND MEDICAL DEVICE |
CN112638288B (zh) | 2018-09-27 | 2024-03-08 | 泰尔茂株式会社 | 愈合促进设备 |
JP7386232B2 (ja) | 2019-03-28 | 2023-11-24 | テルモ株式会社 | 医療デバイス |
JP7377258B2 (ja) | 2019-03-28 | 2023-11-09 | テルモ株式会社 | 医療デバイス |
WO2020196882A1 (ja) | 2019-03-28 | 2020-10-01 | テルモ株式会社 | 癒合促進デバイス |
JP7390361B2 (ja) | 2019-03-28 | 2023-12-01 | テルモ株式会社 | 癒合促進デバイス |
WO2021051003A1 (en) | 2019-09-13 | 2021-03-18 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations of methotrexate |
US11911499B2 (en) | 2019-11-07 | 2024-02-27 | Resurge Therapeutics, Inc. | System and method for prostate treatment |
CN113262302B (zh) * | 2020-02-17 | 2022-12-09 | 湖州惠中济世生物科技有限公司 | 可注射长效半固体凝胶制剂 |
FI20215186A1 (en) * | 2021-02-19 | 2022-08-20 | Rebio Tech Oy | Compositions for ophthalmic treatment |
US11197819B1 (en) * | 2021-04-09 | 2021-12-14 | Drug Delivery Company, Llc | Extended release bioabsorbable subcutaneous medicinal dosage delivery implant system |
CN115463217B (zh) * | 2021-06-11 | 2024-03-12 | 深圳埃格林医药有限公司 | 己酸羟孕酮在增强肿瘤治疗效果中的应用 |
JPWO2023032692A1 (es) | 2021-09-03 | 2023-03-09 | ||
US11602516B1 (en) | 2022-01-29 | 2023-03-14 | Resurge Therapeutics Inc. | Treating benign prostatic hyperplasia |
US11957654B2 (en) | 2022-01-29 | 2024-04-16 | Resurge Therapeutics, Inc. | Treating benign prostatic hyperplasia |
US11911385B1 (en) | 2022-12-14 | 2024-02-27 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3119739A (en) | 1961-05-03 | 1964-01-28 | Wanda L Campbell | Acetylmethyl-salicylate for pain relief |
US4126681A (en) | 1975-12-08 | 1978-11-21 | The Procter & Gamble Company | Topical composition containing acetyl salicylic acid |
US4096271A (en) * | 1977-08-03 | 1978-06-20 | American Cyanamid Company | Slow release injectable formulations of tetramisole and derivatives in benzyl benzoate |
US4244948A (en) | 1979-05-07 | 1981-01-13 | Allergan Pharmaceuticals, Inc. | Medical use of esters of acetylsalicylic acid to treat acne |
US4568547A (en) | 1979-08-30 | 1986-02-04 | Herschler R J | Solid pharmaceutical compositions comprising MSM and their production |
US4309996A (en) * | 1980-04-28 | 1982-01-12 | Alza Corporation | System with microporous releasing diffusor |
US4304765A (en) * | 1980-10-14 | 1981-12-08 | Alza Corporation | Ocular insert housing steroid in two different therapeutic forms |
US4454122A (en) | 1981-04-27 | 1984-06-12 | Bioresearch S.R.L. | Adenosine derivatives of anti-inflammatory and analgesic activity, and therapeutic compositions which contain them as their active principle |
JP2551756B2 (ja) * | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
JPH0662441B2 (ja) * | 1986-02-18 | 1994-08-17 | 花王株式会社 | 抗腫瘍物質徐放性製剤 |
US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
US5371078A (en) * | 1988-10-31 | 1994-12-06 | Alcon Laboratories, Inc. | Angiostatic steroids and methods and compositions for controlling ocular hypertension |
US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
AU653325B2 (en) * | 1990-02-12 | 1994-09-29 | Lucky Limited | A composition durably releasing bioactive polypeptides |
US5620700A (en) * | 1990-10-30 | 1997-04-15 | Alza Corporation | Injectable drug delivery system and method |
AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
JP3220331B2 (ja) | 1993-07-20 | 2001-10-22 | エチコン・インコーポレーテツド | 非経口投与用の吸収性液体コポリマー類 |
WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
WO1995003807A1 (en) | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
SE9403160D0 (sv) * | 1994-09-21 | 1994-09-21 | Pharmacia Ab | Method and means for prevention and treatment of secondary cataract |
US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US6369116B1 (en) | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
US5736152A (en) * | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
DK0959873T3 (da) | 1996-12-20 | 2006-07-03 | Alza Corp | Gelsammensætning og fremgangsmåder |
US20030216303A1 (en) * | 1998-03-06 | 2003-11-20 | Michael Ambuhl | Emulsion preconcentrates containing cyclosporin or a macrolide |
US6733767B2 (en) | 1998-03-19 | 2004-05-11 | Merck & Co., Inc. | Liquid polymeric compositions for controlled release of bioactive substances |
WO1999065916A1 (en) * | 1998-06-15 | 1999-12-23 | Takeda Chemical Industries, Ltd. | Thienodipyridine derivatives, production and use thereof |
ID28460A (id) * | 1998-07-08 | 2001-05-24 | Lipogenics Inc | Komposisi dan metoda untuk perlakuan dan pencegahan penyakit tulang dengan menggunakan tocotrienol |
US6174540B1 (en) | 1998-09-14 | 2001-01-16 | Merck & Co., Inc. | Long acting injectable formulations containing hydrogenated caster oil |
US6537566B1 (en) | 1999-03-11 | 2003-03-25 | John Alton Copland | Compositions and methods for the non-invasive treatment of uterine fibroid cells |
EP1169033A2 (en) * | 1999-04-02 | 2002-01-09 | Washington State University Research Foundation | Enhanced tissue and subcellular delivery of vitamin e compounds |
DE19923551A1 (de) * | 1999-05-21 | 2000-11-30 | Lohmann Therapie Syst Lts | Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht |
BR0010794A (pt) | 1999-05-24 | 2002-06-04 | Sonus Pharma Inc | Emulsão-veìculo para drogas com fraca solubilidade |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US20010049366A1 (en) * | 2000-02-09 | 2001-12-06 | Alcon Universal Ltd. | Topical solution formulations containing an antibiotic and a corticosteroid |
EP1278517B1 (en) | 2000-03-17 | 2007-05-30 | Avocet Polymer Technologies, Inc. | Methods for improving size and appearance of a wound |
KR100365678B1 (ko) * | 2000-03-24 | 2002-12-26 | 주식회사 엘지생명과학 | 주사능이 개선된 소마토트로핀 조성물 |
US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
JP2004506698A (ja) * | 2000-08-23 | 2004-03-04 | アクゾ・ノベル・エヌ・ベー | ヒトに用いるためのテストステロンエステル製剤 |
US6827931B1 (en) * | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
DK1339438T3 (da) | 2000-11-29 | 2006-02-13 | Allergan Inc | Forebyggelse af transplantatafvisning i ojet |
CA2436361C (en) * | 2001-01-29 | 2010-11-02 | Takeda Chemical Industries, Ltd. | Angiotensin ii antagonistic compound for use as analgesic and antiinflammatory agent |
US6653992B1 (en) * | 2001-02-28 | 2003-11-25 | Varian Medical Systems, Inc. | Method and circuit for reduction of correlated noise |
CA2472578A1 (en) * | 2002-01-24 | 2003-07-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Anti-cancer combination and use thereof |
US7074426B2 (en) | 2002-03-27 | 2006-07-11 | Frank Kochinke | Methods and drug delivery systems for the treatment of orofacial diseases |
US6960346B2 (en) * | 2002-05-09 | 2005-11-01 | University Of Tennessee Research Foundation | Vehicles for delivery of biologically active substances |
EP1531827A4 (en) * | 2002-05-24 | 2009-07-08 | Univ Michigan | COPPER-REDUCING TREATMENT FOR INFLAMMATORY AND FIBROTIC DISEASES |
EP2030611A1 (en) * | 2002-07-31 | 2009-03-04 | Alza Corporation | Injectable multimodal polymer depot compositions and uses thereof |
WO2004026281A2 (en) * | 2002-09-23 | 2004-04-01 | Microchips, Inc. | Micro-reservoir osmotic release systems and microtube array device |
US20050143363A1 (en) * | 2002-09-29 | 2005-06-30 | Innorx, Inc. | Method for subretinal administration of therapeutics including steroids; method for localizing pharmacodynamic action at the choroid of the retina; and related methods for treatment and/or prevention of retinal diseases |
US6653288B1 (en) | 2002-09-30 | 2003-11-25 | Virbac S.A. | Injectable anthelmintic compositions and methods for using same |
CA2504608C (en) | 2002-11-06 | 2013-01-08 | Alza Corporation | Controlled release depot formulations |
US7354574B2 (en) | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
US7399784B2 (en) * | 2002-11-26 | 2008-07-15 | Children's Hospital & Research Center At Oakland | Tocopherol and tocotrienol anti-obesity medicaments |
WO2004058272A1 (en) * | 2002-12-20 | 2004-07-15 | Control Delivery Systems, Inc. | Steroid compositions for intraocular use |
JP2007525429A (ja) * | 2003-03-11 | 2007-09-06 | キューエルティー ユーエスエー,インコーポレイテッド. | 細胞スケジュール依存性抗癌剤のための処方 |
US20050118206A1 (en) * | 2003-11-14 | 2005-06-02 | Luk Andrew S. | Surfactant-based gel as an injectable, sustained drug delivery vehicle |
US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
ATE401054T1 (de) * | 2004-06-04 | 2008-08-15 | Camurus Ab | Flüssige depotformulierungen |
SI2415484T1 (sl) * | 2004-09-17 | 2014-10-30 | Durect Corporation | Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem |
-
2005
- 2005-09-27 BR BRPI0516830-9A patent/BRPI0516830A/pt not_active Application Discontinuation
- 2005-09-27 EP EP12000880A patent/EP2452670A1/en not_active Ceased
- 2005-09-27 EP EP17150503.5A patent/EP3173072A1/en not_active Withdrawn
- 2005-09-27 CN CN201010169341.3A patent/CN101890167B/zh active Active
- 2005-09-27 CN CN2005800397759A patent/CN101060831B/zh active Active
- 2005-09-27 CA CA2582096A patent/CA2582096C/en active Active
- 2005-09-27 EP EP05804034A patent/EP1793803B1/en active Active
- 2005-09-27 AU AU2005292145A patent/AU2005292145C1/en active Active
- 2005-09-27 WO PCT/US2005/034822 patent/WO2006039336A2/en active Application Filing
- 2005-09-27 US US11/236,426 patent/US7906136B2/en active Active
- 2005-09-27 MX MX2007003968A patent/MX2007003968A/es active IP Right Grant
- 2005-09-27 MX MX2011005101A patent/MX344532B/es unknown
- 2005-09-27 NZ NZ554426A patent/NZ554426A/en unknown
- 2005-09-27 KR KR1020137028317A patent/KR101506925B1/ko active IP Right Grant
- 2005-09-27 JP JP2007534731A patent/JP5682991B2/ja active Active
- 2005-09-27 MX MX2016016614A patent/MX366832B/es unknown
- 2005-09-27 KR KR1020077009976A patent/KR101341359B1/ko active IP Right Grant
-
2006
- 2006-03-27 MY MYPI20061332A patent/MY167123A/en unknown
-
2007
- 2007-12-06 HK HK07113369.9A patent/HK1107672A1/xx unknown
-
2011
- 2011-05-17 AU AU2011202288A patent/AU2011202288B2/en active Active
-
2012
- 2012-01-18 JP JP2012008366A patent/JP2012072196A/ja not_active Withdrawn
-
2014
- 2014-05-30 JP JP2014112629A patent/JP6342716B2/ja active Active
-
2016
- 2016-09-05 JP JP2016172955A patent/JP2016199596A/ja active Pending
-
2018
- 2018-03-16 JP JP2018049492A patent/JP6650479B2/ja not_active Expired - Fee Related
- 2018-06-07 JP JP2018109586A patent/JP2018135400A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY167123A (en) | Conveniently implantable sustained release drug compositions | |
TW200515919A (en) | Bioerodible sustained release drug delivery systems | |
LTPA2017009I1 (lt) | Brutono tirozinkinazės inhibitoriai | |
EP2322219A3 (en) | Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease | |
CY1118179T1 (el) | Φαρμακευτικη συνθεση | |
DE602005010788D1 (de) | Pharmazeutische Zusammensetzungen zur sicheren Verabreichung von bei der Behandlung von Drogenabhängigkeit verwendeten Arzneimitteln | |
TNSN08079A1 (en) | Pharmaceutical compositions for the treatment of inner ear disorders | |
IS7431A (is) | Samrunaefnasambönd lyfja eða frumudrepandi efna og líffræðilega virkra peptíða | |
WO2006023130A3 (en) | Biodegradable controlled release bioactive agent delivery device | |
WO2005117919A3 (en) | Delayed-setting calcium phosphate pastes | |
PT1401501E (pt) | Composicoes farmaceuticas orais com libertacao modificada do ingrediente activo | |
EP1691789A4 (en) | CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES | |
GB2431346C (en) | A combination composition comprising paracetamol and ibuprofen | |
EA200702522A1 (ru) | Система доставки лекарств в полость рта и способы ее применения | |
EA200501819A1 (ru) | Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке | |
WO2004034975A3 (en) | Sustained release profile modification | |
MXPA05012358A (es) | Combinacion farmaceutica que comprende modafinilo y otra droga. | |
MXPA06002722A (es) | Composicion farmaceutica que comprende un antagonista del receptor p2x7 y un farmaco anti-inflamatorio no esteroidal. | |
TW200509998A (en) | Controlled release of highly soluble agents | |
HK1120417A1 (en) | Stable nanoparticle formulations | |
EP2161037A3 (en) | Camptothecin-Somatostatin conjugates | |
EA201170004A1 (ru) | Использование антагонистов h4-гистаминовых рецепторов для лечения послеоперационных спаек | |
MY169854A (en) | Conveniently implantable sustained release drug compositions | |
TW200726472A (en) | Conveniently implantable sustained release drug compositions | |
WO2005011589A3 (en) | Drug delivery methods and devices |